Skip to main content
SpringerLink
Log in

European CHMP to review Multaq after cases of liver failure

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. European Medicines Agency.Benefit-risk review of Multaq started. Internet Document: [1 page], 21 Jan 2011. Available from: URL: http://www.ema.europa.eu

  2. European Medicines Agency.Meeting highlights from the Committee for Medicinal Products for human use (CHMP): 17-20 January 2011. Internet Document: [4 pages], 21 Jan 2011. Available from: URL: http://www.ema.europa.eu

  3. Sanofi Aventis.Information on severe liver injury associated with the use of Multaq (dronedarone). Internet Document: [2 pages], 19 Jan 2011. Available from: URL: http://www.mhra.gov.uk

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

European CHMP to review Multaq after cases of liver failure. React. Wkly. 1336, 2 (2011). https://doi.org/10.2165/00128415-201113360-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201113360-00002

Keywords

Search

Navigation